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British Sleep Society (BSS) webinar
The current pandemic caused by a novel coronavirus, 
named COVID-19, holds the entire world to ransom. A 
proportion of the infected patients becomes critically ill, 
with millions being infected and hundreds of thousands 
who have died so far. In some countries, national lockdown 
restrictions are being slowly lifted, but the World Health 
Organization (WHO) still registers increasing numbers of 
confirmed COVID-19 infections across its membership 
states. 
Against this background, the BSS brought together 
doctors from the respiratory and critical care response 
teams in Wuhan, China and London, UK in a webinar 
to exchange their knowledge and expertise and discuss 
current best practice in the management of patients with 
COVID-19. Following their presentations, sleep experts 
from the Executive Committee of the BSS discussed the 
impact of the pandemic and lockdown on sleep and shared 
practical advice regarding sleep health. 
Respiratory and critical care response to the 
COVID-19 pandemic
Professor Fengming Luo and Dr. Wanhong Yin from the 
West China Hospital of Sichuan University, China were 
involved in the direct respiratory and critical care response 
team during the outbreak of the pandemic in Wuhan. 
They gave an overview about the logistics, the medical 
and infrastructure measures taken and the difficulties that 
they had to overcome facing this novel virus. During the 
outbreak, it became clear that the virus did not only affect 
the lungs, but also the cardiovascular, renal and neurological 
systems. The Chinese workforce developed protocols for 
the use of personal-protective-equipment (PPE; Figure 1), 
prevention of infection, clinical practice and testing-and-
tracing. 
Professor Nicholas Hart from Guy’s & St Thomas’ 
NHS Foundation Trust (GSTT) in London then spoke 
about the NHS Response to COVID-19 in the London 
area. Prof. Hart is the Clinical Director for Pulmonary, 
Adult Critical Care and Sleep (PACCS) and as such was 
involved in the South London Respiratory and Critical 
Care Network planning during the COVID-19 pandemic, 
the area most hit by the pandemic in the UK (1). The 
first patient with COVID-19 at GSTT was admitted to 
intensive care on the 3rd March 2020 and, following a better 
understanding of the disease, triggered a comprehensive 
integration between acute medicine, anaesthesia, infectious 
diseases, respiratory and critical care that allowed for a rapid 
expansion of hospital capacity (Figure 2). Surgical elective 
interventions were reduced and a planned expansion of 
the critical care area to 234 critical care beds was initiated. 
The redeployment of staff required training of some 
1,550 clinical and many more non-clinical staff, accessing 
education and online training and videos; this included 
245 junior and senior doctors and 473 nurses. Critical 
Care, Respiratory, Thrombosis and Renal Pathways were 
established, ‘lines’ and ‘intubation’ teams, as well as ‘proning’ 
teams started to work non-stop. Virtual communication 
‘lifelines’, were initiated with families and next of kin 
to allow to them to virtually “visit” their loved ones via 
videocalls. Ventilator and equipment procurement were 
coordinated for South London and data analytics support 
was provided centrally. 
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Figure 1 “Donning” procedure of the Chinese Wuhan response team.
2. Wear working cap
3. Wear working clothes
4. Inspect and wear the gloves
5. Secure the gloves 6. Wear protective 
shoe covers 
7. Wear protective suit
8. Wear outer mask
9. Wear outer 
gloves
10. Wear goggles 
or face shield
1. Wear medical protective mask
South London saw the peak of the first wave in the first 
half of April with steadily declining numbers of critically 
ill patients thereafter. Critical care bed capacity was not 
breached: at the peak there were 130 patients at any given 
time under the care of GSTT. This compares to a planned 
critical care bed capacity of 99 beds for the winter season 
with influenza.
Pathophysiology
Profs Luo, Yin and Hart described how, in the first week 
of the infection, patients typically experience a viral 
pneumonia, with subsequent weeks causing an increased 
drive to breathe, acute lung injury, acute cardiac and 
skeletal muscle injury, possible kidney and liver injury 
and intestinal involvement. There is some suggestion of 
two phenotypes of acute respiratory distress syndrome 
(ARDS): type ‘L’ describes patients with low elastance, high 
compliance and low V/Q ratio; type ‘H’ includes patients 
with high elastance and low compliance (<30 mL/H2O) 
and high right-to-left shunt (2). Neural respiratory drive 
was generally high due to the increased work of breathing, 
high transpulmonary pressures and shearing forces, and 
this was complicated by worsening pulmonary oedema and, 
over time, developing fibrotic changes. Closing capacity of 
the airway was often reached, particularly in obesity, with 
microtrauma worsening the oedema with every breath. 
An increased positive end-expiratory ventilation pressure 
(PEEP) during ventilation was found to be helpful to avoid 
this and recruit lung volumes. Pulmonary vessels were 
exposed to significant hypoxic vasoconstriction, due to the 
Euler-Liljestrand effect, and acute pulmonary hypertension 
developed.
Post-critical care follow up
Prof. Hart explained that in patients who were discharged 
from critical care at GSTT, about 50% of patients 
underwent regular post critical care rehabilitation, 25% 
required complex respiratory and 25% complex renal 
support; 70% of tracheostomised patients survived, about 
10% of tracheostomised patients died, and 30% had 
weaned successfully by the time of the webinar. Post critical 
care follow up at 4–6 weeks included 1,136 patients with 
a mortality of 19%, 7% of the patients still remaining 
inpatients at that time. However, half of the patients in 
the follow up clinics had returned to their pre-COVID-19 
baseline. The most common pathologies identified at 
3Journal of Thoracic Disease, 2020
© Journal of Thoracic Disease. All rights reserved.   J Thorac Dis 2020 | http://dx.doi.org/10.21037/jtd-2020-059
Figure 2 Respiratory and critical care treatment algorithm at Guy’s & St Thomas’ NHS Foundation Trust, London, UK.
Titrate FiO2 to Target SpO2
(92-96% for the majority of patients)
Management of Respiratory Failure
Suspected or Confirmed COVID-19
SpO2 in target with FiO² ≥0.6
or RR≥25/min
And no ceiling of escalation
SpO2 in target with FiO2 S0.4
and RR ≤24/min
CRT Review
Work of Breathing
Intubation + MV (Call MErIT)
Volume Control ventilation
• Tidal Volume 8 mL/Kg PBW
• PEEP 8 cmH2O
• RRz—initially to ETCO2 4-5 kPa
Awake proning trial on ward or HDU
Admit to HDU if FiO2 ≥0.6 for ≥4 hrs
And/or if out of hours
Review as per escalation Plan
If peri- arrest
or cardiac arrest
bleep HCID 2222
fast bleep CRT & MErIT
from ED
URGENT CRT Review
SpO2 <92%
despite NRBM
And no ceiling of escalation
Ward
Targets on MV: 
• SpO2 92-96%
• PaO2 ≥8 kPa
• PaCO2< 6or pH >7.30
• Pplat ≤28 cmH2O
Is driving pressure <15 cmH2O?
SpO2 <92% with FiO2 ≥0.7
Compliance ≥40 mL/cmH2O
Neuro-Muscular Blockade
Increase PEEP in 2 cmH2O steps
(up to 15 cmH2O)
Consider RM (40 cmH2Ox 10 s)
Reduce Vt to
6 mL/Kg PBW
Keep Vt at
8 mL/Kg PBW
Hypoxaemia refractory to “higher PEEP” and “prone position” for ≥6 hours
(or sooner if life -threatening hypoxaemia or hypercapnia)
Prone Position
Ventilatory settings as above
SpO2 <92% with FiO2 ≥0.7SpO2 <92% with FiO2 ≥0.7
Trial of Pulmonary
vasodilators
(if feasible and available)
Prone-Position
Discuss with ECMO Consultant
ECMO candidate?
Echo
As soon as
feasible
Review Targets and Strategy VV-ECMO
Low
No
No
No
Yes
Yes
Yes
High
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follow up included interstitial lung disease (ILD), including 
organising pneumonia, cardiac and neuropsychiatric issues. 
Insomnia during COVID-19
In the second part of the webinar, the focus was on the 
impact of COVID-19 on sleep and Professor Jason Ellis 
spoke on insomnia during the pandemic. Referencing 
surveys of the public exploring the mental health and sleep 
impacts of COVID-19 from both China (3) and Italy (4), 
Professor Ellis opened by noting that the published data 
suggest that the public worldwide has experienced a major 
mental health burden as a result of the pandemic. In both 
papers, a significant proportion of respondents reported 
that their sleep quality had been affected as a result of the 
pandemic, with 57% of respondents in the Italian survey 
reporting poor sleep quality, as well as high levels of anxiety 
and distress. Both papers found that younger participants 
were more likely to report sleep disturbance, whilst the 
Italian study also found that female sex, fear of contact with 
cases of COVID-19 and uncertainty around COVID-19 
infection increased the likelihood of impaired sleep. 
Professor Ellis proposed a diagnostic for acute insomnia 
comprised of a “trigger” to the sleep disturbance, which 
could be any life event or train of life events, resulting in a 
significant reduction in quality of life, coupled with distress 
at the current situation. The sleep disturbance should occur 
for at least 3 nights per week and last between 3 days and 3 
months (following which the disorder is better characterised 
as chronic insomnia). The severity of acute insomnia can 
be subjectively assessed by the patient as mild, moderate or 
severe, or quantitively as a sleep onset latency and/or wake 
after sleep onset greater than or equal to 30 minutes (5).
Moving to management, Professor Ellis asked “can 
we circumvent the transition from acute to chronic 
insomnia with a ‘single-shot’ of CBT-I?”. Although 
cognitive behavioural therapy for insomnia (CBT-I) is 
well-established for the treatment of chronic insomnia, it 
has been less well-studied in acute insomnia. In addition, 
access to CBT-I is challenging in many areas and countries 
and is often considered too burdensome to perform in 
primary care where, one might argue, it is most likely to 
be beneficial. In a community-based pragmatic parallel 
group randomized controlled trial, forty adults with acute 
insomnia were given either a single 60- to 70-minute 
session of CBT-I (n=20), with an accompanying self-help 
pamphlet, or were wait listed as the control group (n=20) (6). 
All subjects were offered a full individual course of CBT-I 
on completion of the study, regardless of group allocation. 
The major components of the “single shot” CBT-I were 
sleep hygiene advice and sleep education to identify and 
address sleep related dysfunctional thinking; the principles 
and practice of sleep restriction and a pamphlet advising on 
the principles of stimulus control, cognitive control, and the 
use of imagery distraction techniques. 
At follow-up, there was a significant difference in 
Insomnia Severity Index (ISI) scores between those in 
the CBT-I group and those in the control group [t(38) 
=2.24, P<0.05]. Using the criteria of an ISI score <10 being 
indicative of insomnia remission, at follow-up 12 of 20 
participants (60%) in the treatment group had remitted 
compared to 3 of 20 (15%) in the control group. This 
difference in cases at follow-up was significant (χ2=8.64, df 
=1, P<0.003), indicating that this brief CBT-I intervention 
is sufficient to elicit significant improvements in sleep in 
individuals with acute insomnia. In a further study, the 
authors showed that “single shot” group treatment is as 
efficacious as individual treatment (7).
Concluding, Professor Ellis acknowledged that the 
COVID-19 pandemic has had a significant impact on 
individuals’ sleep worldwide and, in the face of an increasing 
incidence of acute insomnia, we must look for effective 
treatment strategies which can be rapidly deployed, with a 
view to circumventing progression to chronic insomnia and 
its attendant impacts on individuals’ mental health. “Single 
shot” CBT-I may provide a pragmatic solution in these 
challenging times. 
BSS statement on sleep-related advice during 
the COVID-19 pandemic
The last talk in the webinar, delivered by Dr. Simon 
Durrant, Treasurer of the BSS, focused on another key part 
of the response to the pandemic from a sleep perspective: 
the release of the COVID-19 Statement on sleep during the 
pandemic by the BSS on 17th April 2020. The decision to 
release a statement was taken in light of increasing evidence 
of COVID-19-related sleep problems, together with 
uncertainty over whether or not patients with obstructive 
sleep apnoea (OSA) should continue with CPAP treatment 
during the pandemic (8,9). The talk reflected the four parts 
of the statement, which first outlines general government 
advice on hygiene and what to do in the event of an 
infection, before moving on to advice specific to sleep.
Clarity around treatment for OSA is especially important 
during the pandemic due to the additional problems 
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patients with existing breathing disorders may experience 
should they contract COVID-19. The BSS position had 
previously been agreed as a signatory to the OSA Alliance 
statement (10), which suggests continuing with treatment 
in the absence of infection but temporarily stopping if 
infected, unless self-isolation in a different bedroom can be 
ensured and the treatment does not worsen symptoms. In 
all cases, communication (remotely) with service providers 
is recommended.
There have been increasing anecdotal reports of 
insomnia during the lockdown, which is perhaps not 
surprising in view of the effects of the pandemic: lockdown 
with reduced exercise opportunity, increased alcohol sales, 
more electronic device usage and heightened stress and 
anxiety around both the pandemic and concerns over 
jobs and livelihoods. Obtaining sufficient daily exercise is 
important for sleep quality as well as general health so it 
is important that any statement contains this. Similarly, 
alcohol consumption may shorten sleep onset latency, 
but does so at the expense of greater time awake after 
sleep onset and shortened REM sleep duration leading to 
standard advice to avoid alcohol consumption in the hours 
leading up to bedtime (11).
One key characteristic of the global lockdown has been 
a substantial increase in the use of electronic devices for 
communication. This has had many benefits but brings 
with it the risk of increased blue light exposure during the 
evening, leading to suppression of melatonin production 
and problems with sleep. Part of the statement focuses 
on this and suggests using low blue light mode and filters 
where possible.
Stress and anxiety play a large part in many—perhaps 
even most—cases of insomnia and in the current situation 
these are both greatly heightened. The last part of the 
BSS statement addresses these underlying causes and their 
impact on sleep quality. Modern therapeutic techniques 
combined with innovative technology are here to yield two 
potential solutions. Mindfulness aims to help people take 
a step back and reconnect with their thoughts and feelings 
more reflectively and apps are freely available to help with 
this, including programmes targeting sleep specifically. 
Meanwhile, CBT-I is available through electronic delivery 
as well as directly by a therapist and has proven effectiveness 
in treating insomnia (12). The European CBT-I Academy 
have released more detailed advice for sleep in the context 
of COVID-19 (13).
The BSS statement is designed to be helpful by 
addressing sleep problems and underlying causes specific to 
the current pandemic. If we can help people to sleep better, 
with the known benefits for immune function, we might yet 
help to improve quality of life in the general population.
Take-home messages 
The unprecedented challenge of COVID-19 has forced 
clinicians across the world to redeploy whole workforces, 
rapidly expand critical care bed capacity, develop new 
working practices and institute strict infection control 
measures across entire hospitals within a matter of days (14). 
This has had to take place against a background of 
developing understanding about the pathophysiology of this 
complex infection, which involves multiple organ systems 
and in particular targets the respiratory system, resulting in 
a form of acute respiratory failure which has been striking 
in the variability of its presentation. 
In addition to the millions who have experienced the 
direct physical effects of the infection, there are more 
individuals who have experienced indirect effects of the 
pandemic lockdown, which has led to widespread anxieties 
about personal and family members’ health, finances and 
job security. These anxieties frequently affect individuals’ 
sleep quality and quantity, with resultant impacts on 
daytime functioning and physical and mental health. The 
BSS have started a National Early Detection Screening 
survey (NEDS) for sleep associated problems. To date, 611 
participants have submitted a response and of those, about 
¾ noticed that their sleep had changed during the pandemic 
lockdown. More than half of the respondents experienced 
disrupted sleep, more than forty percent had difficulties 
falling or staying asleep, while about a quarter felt 
excessively sleepy or developed nightmares. Sleep hygiene 
advice, self-management resources (online) and guidance 
around sleep routines can improve these problems; the BSS 
has therefore published its statement on sleep-related advice 
during the COVID-19 pandemic containing guidance for 
the general population (15). 
The BSS was honoured to play its part in bringing 
expertise and the global medical community together to 
share their knowledge and experience and further the 
understanding of this complex infection and its impacts on 
society.
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